Evidence map›Paper›PMID 39276622›Full record

ArticleVaccine2024

Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June - 1 July 2024.

Philipp Lambach, Sheetal Silal, Alyssa N Sbarra, Natasha S Crowcroft, Kurt Frey, Matt Ferrari, Emilia Vynnycky, C Jessica E Metcalf, Amy K Winter, Laura Zimmerman and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Philipp LambachImmunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Sheetal SilalModelling and Simulation Hub, Africa, University of Cape Town, Cape Town, South Africa; Centre for Global Health, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
Alyssa N SbarraJohns Hopkins Bloomberg School of Public Health, Baltimore, United States. Electronic address: asbarra1@jhu.edu.
Natasha S CrowcroftImmunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Kurt FreyInstitute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, United States.
Matt FerrariPennsylvania State University, State College, United States.
Emilia VynnyckyUKHSA, London, United Kingdom; London School of Hygiene & Tropical Medicine, London, United Kingdom.
C Jessica E MetcalfDepartment of Ecology and Evolutionary Biology, Princeton University, Princeton, United States.
Amy K WinterDepartment of Epidemiology and Biostatistics & Center for the Ecology of Infectious Diseases, University of Georgia, Athens, United States.
Laura ZimmermanCenters for Disease Control and Prevention, Atlanta, United States.
Mitsuki KohImmunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Meru SheelSchool of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Sydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Sun-Young KimSeoul National University, Seoul, South Korea.
Patrick K MunywokiKenya Medical Research Institute, Centre for Global Health Research, Nairobi, Kenya.
Allison PortnoyDepartment of Global Health, Boston University School of Public Health, Boston, United States; Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, United States.
Rakesh AggarwalJawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.
Habib Hasan FarooquiCollege of Medicine, QU Health, Qatar University.
Stefan FlascheCentre for Global Health, Charite, Berlin, Germany.
Alexandra B HoganSchool of Population Health, University of New South Wales, Sydney, Australia.
Kathy LeungSchool of Public Health, The University of Hong Kong, Hong Kong SAR, China.
William J MossJohns Hopkins Bloomberg School of Public Health, Baltimore, United States.
Xuan-Yi WangShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) serves to independently review and evaluate vaccine-related research to maximize the potential impact of vaccination programs. From 28 June - 1 July 2024, IVIR-AC was convened for an ad hoc meeting to discuss new evidence on criteria for rubella vaccine introduction and the risk of congenital rubella syndrome. This report summarizes background information on rubella virus transmission and the burden of congenital rubella syndrome, meeting structure and presentations, proceedings, and recommendations.

Indexed as

Advisory CommitteesRubellaRubella VaccineWorld Health OrganizationHumansImmunization ProgramsRubella Syndrome, CongenitalRubella virusVaccinationRubella VaccineCongenital rubella syndromeIVIR-ACRCVRubella

Identifiers

PMID39276622
PMCPMC11672238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.